Key result
Low dose spironolactone monotherapy significantly reduced systolic blood pressure compared to placebo in patients with stage I essential hypertension (difference -4.5 mmHg, p=0.004).
Why the study?
Does low dose spironolactone monotherapy reduce blood pressure in patients with stage I essential hypertension?
RCT (n=40)
Double-blind
Randomized
Does low dose spironolactone monotherapy reduce blood pressure in patients with stage I essential hypertension?
Low-dose spironolactone monotherapy effectively reduces systolic blood pressure in patients with stage I essential hypertension over a one-month period.
Supports low-dose spironolactone monotherapy for stage I hypertension; confirms systolic BP reduction in this RCT population.
BACKGROUND: High blood pressure (BP) is a common chronic disease needs long life drug consumption to control. Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension. However, there is no study to determine the effects of low dose spironolactone as a first line therapy in treatment of essential hypertension. The aim of this study is to investigate the effect of low dose spironolactone monotherapy in management of essential hypertension. METHODS: In this double blind randomized clinical trial, 40 patients who had stage I essential hypertension were randomly divided into two groups: intervention group received spironolactone 25 milligram once daily for one month and control group received placebo once daily. At the baseline and after one month, 24-hour BP holter-monitoring and serum potassium assay were done. RESULTS: Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004). There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099). CONCLUSIONS: Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.
No takes yet. Share an insight, caveat, or question.
Attar et al. (2018) conducted an RCT in Stage I essential hypertension (n=40). Spironolactone vs. Placebo was evaluated on Change in systolic blood pressure (Difference -4.5 mmHg, p=0.004). Low dose spironolactone monotherapy significantly reduced systolic blood pressure compared to placebo in patients with stage I essential hypertension (difference -4.5 mmHg, p=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: